Tirzepatide improves kidney, cardiovascular function in patients with obesity and HFpEF

The drug tirzepatide improved kidney function and cardiovascular outcomes among patients with obesity and heart failure with preserved ejection fraction (HFpEF) compared with placebo at one year, according to featured clinical research presented at the American College of Cardiology’s Annual Scientific Session (ACC.25) and simultaneously published in JACC.

Leave a Reply